Tharimmune, Inc. (THAR)
NASDAQ: THAR · Real-Time Price · USD
1.374
-0.067 (-4.62%)
May 14, 2025, 2:26 PM - Market open
Tharimmune Employees
As of December 31, 2024, Tharimmune had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$4,161,054
Market Cap
2.90M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3 | 0 | - |
| Dec 31, 2023 | 3 | 1 | 50.00% |
| Dec 31, 2022 | 2 | 0 | - |
| Dec 31, 2021 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
THAR News
- 8 days ago - Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback - Accesswire
- 13 days ago - Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences - Accesswire
- 14 days ago - Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors - Accesswire
- 16 days ago - Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback - Accesswire
- 4 weeks ago - Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors - Accesswire
- 5 weeks ago - Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology - Accesswire
- 6 weeks ago - Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure - Accesswire
- 7 weeks ago - Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha - Accesswire